Bevicra is a monoclonal antibody used in the treatment of various cancers. It works by inhibiting angiogenesis, the process by which tumors develop new blood vessels to sustain their growth. Bevicra specifically binds to vascular endothelial growth factor (VEGF), a protein that promotes the formation of new blood vessels. By neutralizing VEGF, Bevicra starves tumors of their blood supply, inhibiting growth and progression. 

Indications:

• Colorectal Cancer: Advanced or metastatic stages, often in combination with chemotherapy.
• Non-Small Cell Lung Cancer (NSCLC): Metastatic cases, in combination with chemotherapy.
• Renal Cell Carcinoma (RCC): Advanced stages, often combined with interferon alfa.
• Cervical Cancer: Persistent, recurrent, or metastatic cases.
• Glioblastoma: As a second-line treatment.
• Ovarian Cancer: Platinum-resistant and recurrent forms.

Bevicra is a cornerstone in targeted cancer therapy due to its innovative approach to halting tumor growth. However, its use requires careful consideration of patient-specific factors and potential side effects. Collaborating with oncologists and monitoring during treatment ensures the best outcomes for patients.

Side Effects: Hypertension (high blood pressure), Fatigue, Nausea and vomiting, Nosebleeds, Proteinuria (protein in the urine), 

Severe side effects: Gastrointestinal perforations, Hemorrhage, Arterial thromboembolism, Nephrotic syndrome.

Contraindications

• Hypersensitivity to Bevicra or its components
• Active infections or significant recent surgical procedures
• Uncontrolled hypertension

Precautions

• Pregnancy and Lactation: Bevicra may harm the fetus; effective contraception is advised during and after treatment.
• Wound Healing: Therapy should be delayed in patients undergoing major surgery.
• Monitoring: Regular monitoring of blood pressure, kidney function, and signs of bleeding is essential.

Formulation: Bevicra is available as an intravenous infusion.

Typical Dosing: Colorectal Cancer: 5-10 mg/kg every 2 weeks.

NSCLC: 15 mg/kg every 3 weeks.

Dosage varies based on the cancer type, patient condition, and combination regimen.

Storage and Handling

• Store Bevicra vials at 2°C to 8°C (36°F to 46°F).
• Do not freeze or shake the vials.
• Use the prepared solution immediately or within the recommended timeframe.